MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
390.45%
Quick Ratio
349.03%
Cash Ratio
102.59%
Debt to Asset Ratio
27.00%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • Deferred tax assets
    • Cash and cash equivalents
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued collaboration expenses
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
175,677
189,952
165,596
174,858
Short-term investments
350,251
278,141
248,478
177,244
Accounts receivable, net
23,490
23,224
15,594
51,742
Inventory
70,930
73,141
54,895
41,396
Prepaid expenses and other current assets
48,285
29,714
42,614
30,290
Total current assets
668,633
594,172
527,177
475,530
Property and equipment, net
2,575
1,986
1,943
1,655
Operating lease right-of-use assets
8,353
9,334
9,807
10,073
Other long-term assets
10,834
11,162
11,307
8,288
Intangible asset, net
14,750
15,000
15,250
15,500
Deferred tax assets
190,965
193,626
198,149
201,287
Total assets
896,110
825,280
763,633
712,333
Accounts payable
12,404
24,402
2,028
6,150
Accrued collaboration expenses
88,049
75,577
70,015
63,282
Accrued expenses
46,730
32,771
42,020
30,941
Operating lease liabilities
4,012
3,170
2,987
2,696
Other current liabilities
20,052
20,691
22,134
20,523
Total current liabilities
171,247
156,611
139,184
123,592
Non-current deferred revenue
31,811
31,811
31,811
31,811
Non-current operating lease liabilities
4,885
5,855
6,510
7,022
Other long-term liabilities
34,018
25,316
18,522
14,525
Total liabilities
241,961
219,593
196,027
176,950
Ordinary shares value-Common Class A
12
12
12
12
Ordinary shares value-Common Class B
1
1
1
1
Ordinary shares value-Common Class A1
4
4
4
4
Ordinary shares value-Common Class B1
4
4
4
4
Additional paid-in capital
1,069,622
1,045,877
1,029,748
1,011,854
Accumulated other comprehensive loss
-1,380
-665
-25
-155
Accumulated deficit
-414,114
-439,546
-462,138
-476,337
Total shareholders' equity
654,149
605,687
567,606
535,383
Total liabilities and shareholders' equity
896,110
825,280
763,633
712,333
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$350,251K (202.61%↑ Y/Y)Cash and cashequivalents$175,677K (-8.52%↓ Y/Y)Inventory$70,930K (47.22%↑ Y/Y)Prepaid expenses andother current assets$48,285K (48.85%↑ Y/Y)Accounts receivable, net$23,490K (-26.39%↓ Y/Y)Total current assets$668,633K (59.08%↑ Y/Y)Deferred tax assets$190,965K (-7.08%↓ Y/Y)Intangible asset, net$14,750K (-6.35%↓ Y/Y)Other long-termassets$10,834K (32.20%↑ Y/Y)Operating leaseright-of-use assets$8,353K (-18.93%↓ Y/Y)Property and equipment,net$2,575K (139.31%↑ Y/Y)Total assets$896,110K (35.54%↑ Y/Y)Total liabilities andshareholders' equity$896,110K (35.54%↑ Y/Y)Total shareholders'equity$654,149K (32.15%↑ Y/Y)Total liabilities$241,961K (45.63%↑ Y/Y)Accumulated deficit-$414,114K (16.30%↑ Y/Y)Accumulated othercomprehensive loss-$1,380K (-2503.77%↓ Y/Y)Additional paid-in capital$1,069,622K (8.06%↑ Y/Y)Total currentliabilities$171,247K (45.34%↑ Y/Y)Other long-termliabilities$34,018K (267.29%↑ Y/Y)Non-current deferredrevenue$31,811K (0.00%↑ Y/Y)Non-current operating leaseliabilities$4,885K (-32.56%↓ Y/Y)Ordinary sharesvalue-Common Class A$12K (0.00%↑ Y/Y)Ordinary sharesvalue-Common Class B1$4K (0.00%↑ Y/Y)Ordinary sharesvalue-Common Class A1$4K (0.00%↑ Y/Y)Ordinary sharesvalue-Common Class B$1K (0.00%↑ Y/Y)Accrued collaborationexpenses$88,049K (68.07%↑ Y/Y)Accrued expenses$46,730K (29.95%↑ Y/Y)Other currentliabilities$20,052K (11.39%↑ Y/Y)Accounts payable$12,404K (38.50%↑ Y/Y)Operating leaseliabilities$4,012K (59.08%↑ Y/Y)

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Pharmaceuticals International, plc (KNSA)